ID   SK-BR-3/nab-P
AC   CVCL_B6Y6
SY   SK-BR-3/nab-Paclitaxel resistant
DR   cancercelllines; CVCL_B6Y6
DR   Wikidata; Q112041715
RX   DOI=10.4314/tjpr.v20i12.6;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 05-10-23; Version: 5
//
RX   DOI=10.4314/tjpr.v20i12.6;
RA   Tian C.-Y., Xu M.-Z., Zhang H.-X., Liu H.-C., Liu X.-H., Ma L.-H.;
RT   "LINC00173 mediates albumin paclitaxel resistance in breast cancer
RT   cells by regulating beta-catenin expression.";
RL   Trop. J. Pharm. Res. 20:2497-2503(2021).
//